Med. praxi. 2018;15(4):194-196 | DOI: 10.36290/med.2018.037

Viral hepatitis in the office of G.P.

prof. MUDr. Petr Husa, CSc.
Klinika infekčních chorob FN a LF MU Brno

Chronic hepatitis C therapy using Directly Acting Antivirals (DAA) has high efficacy (till 100 %), minimum contra-indications andextraordinarily favorable safety profile. Primarily, it is necessary to pay attention to drug-drug interactions. However they arewell documented and successfully resolvable already in general clinical practice. Current possibilities of interferon-free therapyrepresent combinations of sofosbuvir with other DAA (velpatasvir, velpatasvir + voxilaprevir, ledipasvir), combination of paritaprevirboosted by ritonavir + ombitasvir ± dasabuvir, and fixed combinaton of elbasvir and grazoprevir. Fixed combinations ofglecaprevir + pibrentasvir will be available in the Czech Republic during the year 2018.

Keywords: viral hepatitis C, hepatologist, general practitioner, multi-discipline cooperation

Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Husa P. Viral hepatitis in the office of G.P. Med. praxi. 2018;15(4):194-196. doi: 10.36290/med.2018.037.
Download citation

References

  1. Wold Health Organization. Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection. Updated version April 2016. Dostupné na: www.who.int/hiv/topics/hepatitis/en.
  2. European Association for the Study of Liver. EASL recommendations on treatment of hepatitis C 2016. Summary. Dostupné na: www.easl.eu/medias/cpg/HCV2016/Summary.pdf.
  3. Urbánek P, Husa P, Šperl J, et al. Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C. Klin mikrobiol inf lek 2017; 23(1): 22-40.
  4. Husa P. Extrahepatální manifestace infekce HCV. Acta medicinae 2017; 6(9): 87-90.
  5. Tillmann HL, McHutchison JG. Hepatitis C. In: Boyer TD, Manns MP, Sanyal A. Zakim and Boyer's Hepatology. Sixth edition. Elsevier Saunders, Philadelphia 2012: 574-576. Go to original source...
  6. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46(Suppl. 5): S165-S173. Go to original source... Go to PubMed...
  7. Younossi Z, Park H, Henry L, et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016; 150: 1599-1608. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.